Remoxy (oxycodone) - Cassava
(+) Corporate Presentation (Durect) - Dec 20, 2012 - "Met Primary Endpoint: Reduction in pain scores over 3 months compared to placebo (p<0.01); Met Secondary Endpoints: Quality of Analgesia (p<0.01), Global Assessment (p<0.01)" 
P3 data • Pain
http://www.larvolonline.com/tlg/ccdb/DurectPharmaCorporatePresentationDec072012.pdf
 
Dec 20, 2012
 
.
 
4701bc11-637d-4d85-bc8f-f77bc32aa773.jpg